Protalix BioTherapeutics (PLX) Operating Margin Growth (3y) (2013 - 2026)
Powered by 
Analysis
Protalix BioTherapeutics (PLX) Operating Margin Growth (3y) (2013 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Operating Margin Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | -347.00 |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | -15,844.00 |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | -377.00 |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | -204.00 |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | 7,045.00 |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | -1,934.00 |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 9,003.00 |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | -2,825.00 |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | -2.41 Mn |
| 10 | Protalix BioTherapeutics | 218.36 Mn | 177.71 Mn | 12.13 Mn | -3,474.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -3,474.00 |
| Mar 31, 2026 | 8,830.00 |
| Dec 31, 2025 | -2,211.00 |
| Sep 30, 2025 | 3,397.00 |
| Jun 30, 2025 | 7,059.00 |
| Mar 31, 2025 | -2,936.00 |
| Dec 31, 2024 | 10,632.00 |
| Sep 30, 2024 | 3,786.00 |
| Jun 30, 2024 | 12,460.00 |
| Mar 31, 2024 | -9,683.00 |
| Dec 31, 2023 | -6,811.00 |
| Sep 30, 2023 | 569.00 |
| Jun 30, 2023 | 7,865.00 |
| Mar 31, 2023 | -4,733.00 |
| Dec 31, 2022 | -4,469.00 |
| Sep 30, 2022 | -1,120.00 |
| Jun 30, 2022 | -1,543.00 |
| Mar 31, 2022 | 4,139.00 |
| Dec 31, 2021 | -2,403.00 |
| Sep 30, 2021 | 54,862.00 |